NCT00968890View on ClinicalTrials.gov

Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly

PHASE2CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

September 12, 2009

Primary Completion Date

September 23, 2010

Study Completion Date

September 23, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

Pandemrix (Influenza vaccine GSK2340272A)

Intramuscular injection, 2 doses

BIOLOGICAL

Fluarix™

Intramuscular injection, 1 dose

BIOLOGICAL

Placebo

Intramuscular injection, 1 dose

Trial Locations (2)

SE-631 88

GSK Investigational Site, Eskilstuna

SE-703 62

GSK Investigational Site, Örebro

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY